Research & Development

Imagine a world where life-altering therapies for genetic disorders, cancer, and infectious diseases are not just a distant dream but a tangible reality, delivered precisely to the cells that need them most. RNA therapeutics hold this transformative promise, yet their potential remains locked

Ivan Kairatov has spent years at the crossroads of oncology and drug development, translating trial signals into day-to-day decisions for patients with localized prostate cancer. In this conversation, he unpacks new evidence showing that most of the value from androgen deprivation therapy (ADT)

Imagine a world where a diagnosis of gastric cancer no longer carries the weight of a dire prognosis, where innovative treatments offer a real chance at long-term survival even for those in the early stages of this aggressive disease. This vision is inching closer to reality with the recent

A therapy that should unleash the immune system instead fuels a tumor’s growth, and the only way to see why is to listen to each cell speak for itself; that is the everyday paradox that single-cell RNA sequencing (scRNA-seq) now makes decipherable in real time. In oncology, this shift from average

Imagine a world where a lung cancer diagnosis no longer feels like a death sentence, but rather a challenge that can be managed with the right tools and support. For too long, this disease has carried a heavy burden of fear and stigma, often seen as an unstoppable force due to its high mortality

In cancer trials where survival curves dominate headlines yet leave the lived experience in the margins, a new consensus promises to pull patient voices into the center of decision-making by standardizing how those voices are captured, analyzed, and reported. Patient-reported outcomes (PROs) have